Technology Highlights

Key Highlights

SCD-2101 is a novel Chinese herbal medicine developed for functional constipation with Yang deficiency. It combines traditional prescriptions with modern pharmaceutical technologies to deliver improved efficacy, safety, patient compliance, and clear modern clinical indications, supporting FDA and NMPA new drug applications.

Challenges

• High prevalence of functional constipation with Yang deficiency (~10%)
• Limited efficacy and frequent adverse events of existing single-target agents Industry Applications
• Botanical drug development and regulatory submissions (IND/NDA)
•  No approved Chinese medicine specifically for constipation with Yang deficiency
• Poor adherence to conventional large-dose herbal formulations 

Breakthrough Technology

• Multi-component Chinese herbal formulation targeting multi-pathway constipation mechanisms
• Traditional granules and direct-swallow dosage form tailored to different age population to improve compliance
• Development aligned with both NMPA and FDA standards to enable dual IND submissions
• Clear modern disease indication specifically for functional constipation with Yang deficiency
• Real-world clinical evidence generation to accelerate development and market access

Industry Applications

• Botanical drug development and regulatory submissions (IND/NDA)
• Pharmaceutical licensing and technology transfer
• International market entry for modernised Chinese medicine products

Business Benefits

• Targets a large and growing population with functional constipation of Yang deficiency
• Differentiated product with clear clinical positioning
• Strong IP and licensing potential with industry partners
• Accelerated path to market via a regulatoryready development strategy
• Scalable across China, the US, and global market